Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach

Older chronic lymphocytic leukemia patients have poor outcomes with standard treatments and are underrepresented in clinical trials. We retrospectively reviewed outcomes of refractory chronic lymphocytic leukemia patients in two age categories (≥70 and <70 years) treated with single-agent flavopi...

Full description

Saved in:
Bibliographic Details
Main Authors: Stephens, Deborah M., Ruppert, Amy S., Blum, Kristie, Jones, Jeffrey, Flynn, Joseph M., Johnson, Amy J., Ji, Jia, Phelps, Mitch A., Grever, Michael R., Byrd, John C.
Format: Artigo
Language:Inglês
Published: Ferrata Storti Foundation 2012
Subjects:
Original Articles and Brief Reports
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3291598/
https://ncbi.nlm.nih.gov/pubmed/22271900
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.047324
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items